(S)-WAY 100135 dihydrochloride5-HT1A receptor antagonist,potent and selective CAS# 149007-54-5 |
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 149007-54-5 | SDF | Download SDF |
| PubChem ID | 14801905 | Appearance | Powder |
| Formula | C24H35Cl2N3O2 | M.Wt | 468.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 5 mM in water with gentle warming and to 10 mM in water with sonication | ||
| Chemical Name | N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide;dihydrochloride | ||
| SMILES | CC(C)(C)NC(=O)C(CN1CCN(CC1)C2=CC=CC=C2OC)C3=CC=CC=C3.Cl.Cl | ||
| Standard InChIKey | VJGZNBYDSDEOED-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H33N3O2.2ClH/c1-24(2,3)25-23(28)20(19-10-6-5-7-11-19)18-26-14-16-27(17-15-26)21-12-8-9-13-22(21)29-4;;/h5-13,20H,14-18H2,1-4H3,(H,25,28);2*1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent, selective 5-HT1A receptor antagonist (IC50 = 15 nM). Selective over 5-HT1B, 1C, 2,α1, α2 and D2 receptors (IC50 > 1000 nM). Centrally active on systemic administration. |
(S)-WAY 100135 dihydrochloride Dilution Calculator
(S)-WAY 100135 dihydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1346 mL | 10.673 mL | 21.3461 mL | 42.6922 mL | 53.3652 mL |
| 5 mM | 0.4269 mL | 2.1346 mL | 4.2692 mL | 8.5384 mL | 10.673 mL |
| 10 mM | 0.2135 mL | 1.0673 mL | 2.1346 mL | 4.2692 mL | 5.3365 mL |
| 50 mM | 0.0427 mL | 0.2135 mL | 0.4269 mL | 0.8538 mL | 1.0673 mL |
| 100 mM | 0.0213 mL | 0.1067 mL | 0.2135 mL | 0.4269 mL | 0.5337 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
(S)-WAY 100135 dihydrochloride is a potent and selective antagonist of 5-HT1A receptor with IC50 value of 15 nM.
The 5-HT1A receptor is a G protein-coupled receptor for endogenous neurotransmitter serotonin (5-HT) and mediates inhibitory neurotransmission.
(S)-WAY 100135 dihydrochloride is a potent and selective somatodendritic and postsynaptic 5-HT1A receptors antagonist. (+/-)-WAY100135 inhibited 5-HT1A receptor in the rat hippocampal with IC50 value of 34 nM [1].
In the murine elevated plus-maze test, (S)-WAY 100135 (10 mg/kg) exhibited anxiolytic-like effects [2]. In free feeding rats, WAY-100135 (3 mg/kg) significantly inhibited hyperphagia and the increased incidence of feeding induced by 8-OH-DPAT (0.1 mg/kg), which was mediated by somatodendritic 5-HT1A autoreceptor [3]. In rats, (S)-WAY 100135 (0.2, 1, 5 ug/ul) inhibited the impairment of choice accuracy induced by intrahippocampal scopolamine (3.75 ug/ul) in a dose-dependent way. However, (S)-WAY 100135 didn’t influence the acquisition of spatial learning [4]. In rats, WAY-100135 (10.0 mg/kg) inhibited the decrease of 5-HT release induced by buspirone, a 5-HT1A receptor partial agonist [5].
References:
[1]. Fletcher A, Bill DJ, Bill SJ, et al. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur J Pharmacol, 1993, 237(2-3): 283-291.
[2]. Rodgers RJ, Cole JC. Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur J Pharmacol, 1994, 261(3): 321-325.
[3]. Hartley JE, Fletcher A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur J Pharmacol, 1994, 252(3): 329-332.
[4]. Carli M, Luschi R, Samanin R. (S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Eur J Pharmacol, 1995, 283(1-3): 133-139.
[5]. Routledge C, Gurling J, Ashworth-Preece MA, et al. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur J Pharmacol, 1995, 276(3): 281-284.
- Dexrazoxane HCl (ICRF-187, ADR-529)
Catalog No.:BCC1087
CAS No.:149003-01-0
- D-Isomenthol
Catalog No.:BCN8540
CAS No.:23283-97-8
- Gallic acid
Catalog No.:BCN1668
CAS No.:149-91-7
- Scopolamine butylbromide
Catalog No.:BCN5006
CAS No.:149-64-4
- Erythritol
Catalog No.:BCN1664
CAS No.:149-32-6
- Fmoc-Inp-OH
Catalog No.:BCC3266
CAS No.:148928-15-8
- 3-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl-2-propenal
Catalog No.:BCC8600
CAS No.:148901-68-2
- Fmoc-L-Arg(Aloc)2-OH
Catalog No.:BCC2564
CAS No.:148893-34-9
- HATU
Catalog No.:BCC2813
CAS No.:148893-10-1
- YM 511
Catalog No.:BCC6002
CAS No.:148869-05-0
- Ivabradine HCl
Catalog No.:BCC4350
CAS No.:148849-67-6
- Rutamarin
Catalog No.:BCN7509
CAS No.:14882-94-1
- H-D-Trp-OMe.HCl
Catalog No.:BCC3118
CAS No.:14907-27-8
- Brusatol
Catalog No.:BCN8278
CAS No.:14907-98-3
- AG 825
Catalog No.:BCC7113
CAS No.:149092-50-2
- Brugine
Catalog No.:BCN1899
CAS No.:14912-30-2
- Cratoxylone
Catalog No.:BCN3875
CAS No.:149155-01-1
- Homaloside D
Catalog No.:BCN1661
CAS No.:149155-19-1
- Eriodictyol chalcone
Catalog No.:BCN8276
CAS No.:14917-41-0
- 3-(2,4-Dihydroxybenzyl)-5-hydroxy-7,8-dimethoxy-6-methylchroman-4-one
Catalog No.:BCN6634
CAS No.:149180-48-3
- Irenolone
Catalog No.:BCN7146
CAS No.:149184-19-0
- CGP 54626 hydrochloride
Catalog No.:BCC6934
CAS No.:149184-21-4
- CGP 55845 hydrochloride
Catalog No.:BCC5737
CAS No.:149184-22-5
- (±)-Decanoylcarnitine chloride
Catalog No.:BCC6659
CAS No.:14919-36-9
Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test.[Pubmed:7813555]
Eur J Pharmacol. 1994 Aug 22;261(3):321-5.
The effects of (S)-WAY 100135 ((S)-N-tert-butyl-3-(4-(2-methoxyphenyl)- piperazin-1-yl)-2-phenyl-propanamide dihydrochloride; 2.5-20.0 mg/kg), a 5-HT1A receptor antagonist, on the behaviour of male mice were examined in the elevated plus-maze test of anxiety. An ethological scoring technique was used to provide a comprehensive profile of drug action. Only minor changes in behaviour were observed at 2.5 and 5.0 mg/kg, and consisted of reductions in some (though not all) risk assessment measures. At 10 mg/kg, the compound increased percent open arm entries and percent open arm time, without altering general activity levels. This classic anxiolytic-like profile was confirmed by major reductions in risk assessment measures including protected head-dips and protected stretched attend postures. Although many of the same changes were also observed at 20 mg/kg, the absence of an effect on percent open arm time and a tendency towards increased non-exploratory behaviour suggested (1) some loss of anxiolytic activity and (2) a possible contribution of non-specific factors at higher doses. Present findings indicate that (S)-WAY 100135 produces clear anxiolytic-like effects in the murine elevated plus-maze, a profile that can be distinguished from that produced by 5-HT1A receptor partial agonists in the same test.
WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.[Pubmed:8365456]
Eur J Pharmacol. 1993 Jun 24;237(2-3):283-91.
The novel phenylpiperazine derivative, (+/-)-WAY100135 (N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpro pionamide dihydrochloride), is a selective antagonist at both somatodendritic and postsynaptic 5-HT1A receptors. The IC50 of (+/-)-WAY100135 at the rat hippocampal 5-HT1A receptor was 34 nM, whereas its IC50 at a range of other receptor sites was > 2 microM. Up to a dose of 2.5 mg/kg i.v. (+/-)-WAY100135 induced a maximum 30% inhibition of raphe neuronal firing and (at 0.5 mg/kg i.v.) antagonised the inhibition of firing induced by 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) in anaesthetised rats. (+/-)-WAY100135 antagonised the action of 5-carboxamidoiodotryptamine in the guinea-pig ileum, with a pA2 of 7.2. (+/-)-WAY100135 had no agonist-like behavioural effects but antagonised the behavioural syndrome and hypothermia induced by 8-OH-DPAT in the rat and mouse, respectively. The interaction of (+/-)-WAY100135 with the 5-HT1A receptor was stereoselective; the (+)-enantiomer being markedly more active in binding, functional and behavioural studies. These data indicate that (+/-)-WAY100135 is the first highly selective antagonist at both somatodendritic and postsynaptic 5-HT1A receptors.
Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents.[Pubmed:8122313]
Trends Pharmacol Sci. 1993 Dec;14(12):41-8.
The 5-hydroxytryptamine 5-HT1A receptor has been the focus of considerable research effort for over a decade. However, the definitive classification of this receptor and the full characterization of its pharmacology have awaited the development of highly selective 5-HT1A receptor antagonists. The only compounds available until recently have been either nonselective or partial 5-HT1A receptor agonists (or a combination of both). Confusion has arisen owing to the use of different pharmacological models in examining the functional activity of 5-HT1A receptor ligands. Several partial agonists display only antagonist activity in models of postsynaptic 5-HT1A receptor function, whereas their agonist properties are revealed in models of presynaptic, somatodendritic 5-HT1A autoreceptor function. In view of these considerations, the term 'silent antagonist' has been introduced to distinguish true 5-HT1A receptor antagonists from partial agonists. Allan Fletcher and colleagues review the pharmacological properties of the first selective silent 5-HT1A receptor antagonists that have been recently discovered and discuss the potential therapeutic utility of these novel compounds.
